Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509798 | 1.00 | CASP3 (0.43) | CASP3BCHESMN1; SMN2LMNAHTR2A | |
| SCHEMBL8354507 | 0.93 | BCHE (0.42) | CASP3BCHELMNAALDH1A1 | |
| SCHEMBL8277396 | 0.93 | CASP3 (0.39) | CASP3BCHE | |
| SCHEMBL8278171 | 0.93 | BCHE (0.42) | CASP3BCHELMNAALDH1A1 | |
| SCHEMBL12664613 | 0.93 | CASP3 (0.39) | CASP3BCHESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL12569684 | 0.91 | MEN1 (0.47) | LMNAALDH1A1 | |
| SCHEMBL8278164 | 0.90 | BCHE (0.43) | BCHESMN1; SMN2LMNAHTR2AALDH1A1 | |
| SCHEMBL8346865 | 0.90 | CASP3 (0.38) | CASP3BCHESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1857254 | 0.89 | BCHE (0.41) | BCHESMN1; SMN2LMNAHTR2AALDH1A1 | |
| SCHEMBL1855871 | 0.88 | BCHE (0.40) | BCHESMN1; SMN2LMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1317454-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2295054-A1 | Ice inhibitors for the treatment of autoinflammatory diseases | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2005117846-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267101-A1 | Interleukin-1 beta converting enzyme inhibitor: 3-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-3-formylpropionic acid or 4-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-5-ethoxy-2-tetrahydrofuranone; autoinflammatory diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-12-01 | — | — | US | disclosed |
| EP-1499898-A2 | REGULATION OF TNF-ALPHA | Vertex Pharmaceuticals Incorporated (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6800619-B2 | UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-05 | — | — | US | disclosed |
| US-20040048797-A1 | Regulation of TNF-alpha | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-11 | — | — | US | disclosed |
| WO-2003088917-A2 | REGULATION OF TNF-ALPHA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003088917-A2 | REGULATION OF TNF-ALPHA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1317454-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020058630-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-16 | — | — | US | disclosed |
| WO-2002022611-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058630-A1 | Caspase inhibitors and uses thereof | CASP2, CASP3, CASP7 | CASP3 2/4885BCHE 470/4885SMN1; SMN2 3946/4885 |
| US-20040048797-A1 | Regulation of TNF-alpha | TNF, TNFRSF1A, TNFRSF9 | CASP3 869/4885BCHE 629/4885SMN1; SMN2 3937/4885 |
| US-20050267101-A1 | Interleukin-1 beta converting enzyme inhibitor: 3-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-3-formylpropionic acid or 4-(1-((4-amino-3-chlorobenzoylamino)tert-butylacetyl)-2-pyrrolidinylcarbonylamino)-5-ethoxy-2-tetrahydrofuranone; autoinflammatory diseases | IL1B, IL1A, NFKBIA | CASP3 309/4885BCHE 1917/4885SMN1; SMN2 4653/4885 |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | UACA, SSB, NFKBIA | CASP3 425/4885BCHE 3379/4885SMN1; SMN2 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.